TNFRSF9 TNF receptor superfamily member 9
ENSG00000049249 · protein coding · Open Targets profile
Receptor for TNFSF9/4-1BBL. Conveys a signal that enhances CD8(+) T-cell survival, cytotoxicity, and mitochondrial activity, thereby promoting immunity against viruses and tumors (Probable). .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- Antibody
- Advanced Clinical, GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination
gnomAD loss of function constraint: o/e 0.5549200177192688 (upper bound 0.8428300023078918). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 13 registry trials, updated in the last three years, of the most advanced drugs against TNFRSF9 (utomilumab, urelumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Adrienne WaksDana-Farber Cancer Institute · 1 of 1 trials Phase 2+
- Amir A JazaeriM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Ana De Jesus-AcostaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University · 1 of 1 trials Phase 2+
- Aung NaingM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Noah HahnJohns Hopkins University · 1 of 1 trials Phase 2+
- Amod SarnaikH. Lee Moffitt Cancer Center and Research Institute · 0 of 1 trials Phase 2+
- Caron A. JacobsonDana-Farber Cancer Institute · 0 of 1 trials Phase 2+
- David S HongM.D. Anderson Cancer Center · 0 of 1 trials Phase 2+
- Elizabeth BuddeCity of Hope Medical Center · 0 of 1 trials Phase 2+
Registry trials of utomilumab, urelumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 11 of 13 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.
12 trials of drugs against TNFRSF9 were stopped early; 6 give no reason
Terminated, withdrawn and suspended interventional trials of utomilumab, urelumab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 12 most recent of 12.
- terminated · 2025-02-06 · Dana-Farber Cancer Institute · Utomilumab“Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients already enrolled on study were allowed to continue treatment.”
- terminated · 2024-07-30 · Pfizer · Utomilumab“The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)”
- terminated · 2024-06-28 · Kite, A Gilead Company · Utomilumab“Development program terminated”
- terminated · 2022-12-16 · M.D. Anderson Cancer Center · Utomilumab“Closed the trial for infeasibility due to slow accrual”
- terminated · 2020-12-17 · Pfizer · Utomilumab“Study was terminated due to closure of study arms following futility analysis and difficulty in enrolling participants due to evolving treatment landscape”
- terminated · 2020-10-05 · Bristol-Myers Squibb · UrelumabNo reason given
- terminated · 2019-02-27 · Pfizer · matched by the registry's drug synonyms“The study was terminated due to marginal efficacy and change in sponsor prioritization. The combination had a manageable safety profile.”
- withdrawn · 2016-12-06 · M.D. Anderson Cancer Center · UrelumabNo reason given
- terminated · 2015-10-12 · Bristol-Myers Squibb · matched by the registry's drug synonymsNo reason given
- withdrawn · 2011-11-21 · Bristol-Myers Squibb · matched by the registry's drug synonymsNo reason given
- terminated · 2009-09-04 · Bristol-Myers Squibb · matched by the registry's drug synonymsNo reason given
- terminated · 2009-09-04 · Bristol-Myers Squibb · matched by the registry's drug synonymsNo reason given
Paediatric incentives and obligations for TNFRSF9's drugs
For utomilumab, urelumab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · TNFRSF9 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names utomilumab, urelumabRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names utomilumab, urelumabRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of utomilumab, urelumabRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of utomilumab, urelumabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 1 interventional studies of utomilumab, urelumab include patients under 18; 0 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 2 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.